12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iluvien regulatory update

Alimera said the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved Iluvien to treat vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. The MAA for Iluvien was submitted under the EU's...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >